Mailankody Sharada, Bajpai Jyoti, Budukh Atul, Swaminathan Rajaraman, Dikshit Rajesh, Dhimal Meghnath, Perera Suraj, Tshomo Ugyen, Bagal Sonali, Bhise Mahadev, Chaturvedi Pankaj, Banavali Shripad D, Gupta Sudeep, Badwe Rajendra A, Trama Annalisa
Department of Medical Oncology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Department of Medical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India.
Lancet Reg Health Southeast Asia. 2023 Feb 27;12:100168. doi: 10.1016/j.lansea.2023.100168. eCollection 2023 May.
Rare cancers (RCs) are challenging to manage and are "forgotten cancers" though they collectively constitute a significant proportion of all cancers (∼20%). As a first step towards streamlining care, there is an unmet need to map the epidemiology of RCs in South Asian Association for Regional Collaboration (SAARC) countries.
The authors collected data from 30 Population-Based Cancer Registries (PBCR) of India and the published national registries of Nepal, Bhutan and Sri Lanka (SL) and compared them with the standard RARECAREnet RC list.
With the standard definition of crude incidence rates (CR) ≤6/100,0000 per population, 67.5%, 68.3%, 62.3% and 37% of all incident cancers qualify as RCs in India, Bhutan, Nepal and SL, respectively. An arbitrary cut-off CR ≤3 appears more appropriate with 43%, 39.5%, 51.8% and 17.2% of cancers identified as RCs, respectively, due to the lower cancer incidence.There are similarities and notable differences between the RC lists of the SAARC region with that of the European RC list. Oral cavity cancers are rare in Europe, while pancreas, rectum, urinary bladder and melanomas are common. In addition, uterine, colon and prostatic cancers are rare in India, Nepal and Bhutan. In SL, thyroid cancer is common. There are gender-related and regional differences in RC trends in the SAARC countries.
There is an unmet need in SAARC nations to capture epidemiological nuances in rare cancers. Understanding the unique issues in the developing world may guide policymakers to adopt appropriate measures to improve RC care and tailor public health interventions.
None.
罕见癌症(RCs)的治疗颇具挑战性,尽管它们在所有癌症中占相当大的比例(约20%),却被视为“被遗忘的癌症”。作为简化治疗流程的第一步,绘制南亚区域合作联盟(SAARC)国家罕见癌症的流行病学图谱的需求尚未得到满足。
作者收集了印度30个基于人群的癌症登记处(PBCR)的数据以及尼泊尔、不丹和斯里兰卡(SL)已发表的国家登记数据,并将其与标准的RARECAREnet罕见癌症列表进行比较。
按照每十万人中粗发病率(CR)≤6的标准定义,在印度、不丹、尼泊尔和斯里兰卡,分别有67.5%、68.3%、62.3%和37%的所有新发癌症被归类为罕见癌症。由于癌症发病率较低,采用CR≤3这一任意临界值似乎更为合适,此时分别有43%、39.5%、51.8%和17.2%的癌症被确定为罕见癌症。SAARC地区的罕见癌症列表与欧洲的罕见癌症列表之间存在异同。口腔癌在欧洲较为罕见,而胰腺癌、直肠癌、膀胱癌和黑色素瘤则较为常见。此外,子宫癌、结肠癌和前列腺癌在印度、尼泊尔和不丹较为罕见。在斯里兰卡,甲状腺癌较为常见。SAARC国家的罕见癌症趋势存在性别和地区差异。
SAARC国家在捕捉罕见癌症的流行病学细微差别方面存在需求未得到满足的情况。了解发展中国家的独特问题可能会指导政策制定者采取适当措施来改善罕见癌症的治疗,并调整公共卫生干预措施。
无。